Thromboembolism – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions.
A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery.
The Thromboembolism drugs in development market research report provide comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thromboembolism | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thromboembolism therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thromboembolism pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thromboembolism treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acticor Biotech SASAddpharma Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Alphamab Oncology
Anthos Therapeutics Inc
Bayer AG
Bio-Synectics Inc
Bristol-Myers Squibb Co
Cadrenal Therapeutics Inc
CarboMimetics
China Biologic Products Holdings Inc
China Resources Emde Biological Pharmaceutical Co Ltd
China Resources Pharmaceutical Group Ltd
CSPC Pharmaceutical Group Ltd
EVAS Therapeutics LLC
Guangzhou Recomgen Biotech Co Ltd
Indiana Lysis Technologies LLC
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Jemincare Group Co Ltd
KLUS Pharma Inc
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Lee's Pharmaceutical Holdings Ltd
Mudanjiang Youbo Pharmaceutical Co Ltd
Overseas Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
SupraGen LLC
Suzhou Ribo Life Sciences Co Ltd
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Translational Sciences Inc
University of California Irvine
University of Liege
Verseon Corp
Zonhon Biopharma Institute Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thromboembolism reports